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Rosiglitazone is an anti-diabetic drug in the thiazolidinedione
class of drugs as a peroxisome proliferator-activated receptor-γ
agonist [1,2]. Rosiglitazone is known to be metabolized by
CYP2C8 or CYP2C9 and biotransformed into N-desmethyl
rosiglitazone (N-Dm-RSG) and p-hydroxy rosiglitazone (p-OH-
RSG) [3]. Several animal models of type II diabetes mellitus
have been used for the development of anti-diabetic agents,
and ob/ob mouse is one of the typical models of type II dia-
betes with leptin-deficiency. This study was for the
pharmacokinetic profiling of rosiglitazone and its metabo-
lites N-Dm-RSG and p-OH-RSG in an animal model of diabetes
using ob/ob mice.
Male ob/ob (B6.V-Lepob/J) and control (C57/B6) mice were
used for the pharmacokinetic study of rosiglitazone and its me-
tabolites N-Dm-RSG and p-OH-RSG. Rosiglitazone (5mg/kg dose)
were administered by intravenous or oral administration and
the blood were obtained at the time points from blank to 24 hr.
Samples were analyzed by LC/MS/MS systemwithAB Sciex 4000
QTRAP and Agilent 1200 series HPLC system. Physiological
characteristics were significantly different between control
and ob/ob mice such as body weight and glucose levels. Phar-
macokinetic profiles of rosiglitazone (RSG) and its metabolites,
N-desmethyl rosiglitazone (N-Dm-RSG) and hydroxy
rosiglitazone (OH-RSG) were plotted after 5 mg/kg dose by in-
travenous and oral administration in C57/B6 and ob/ob mice
(Fig. 1). Area under the plasma concentration–time curve
(AUC) levels were 50.8 ± 13.7 mg·hr/ml for control and
66.6 ± 11.8 mg·hr/ml for ob/ob mice, the maximum plasma con-
centrations (Cmax) were 12.9 ± 1.7 mg/ml for control and
14.8 ± 1.9 mg/ml for ob/ob mice, and the time to maximum
plasma concentration (Tmax) were 0.42 ± 0.13 hr for control and
0.55 ± 0.27 hr for ob/ob mice. AUC values were not signifi-
cantly different (50.8 ± 13.7 mg·hr/ml for control and
66.6 ± 11.8 mg·hr/ml for ob/ob mice). Pharmacokinetics of
N-desmethyl rosiglitazone (N-Dm-RSG) in ob/ob mice was dif-
ferent from that in control C57/B6 mice. AUC levels of ob/ob
mice were higher than that of the control C57/B6 mice after
oral administration (5.4 ± 0.91 mg·hr/ml for control and
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9.1 ± 1.4 mg·hr/ml for ob/ob mice). Profiles of hydroxy
rosiglitazone (OH-RSG) were not significantly different between
ob/ob and control C57/B6 mice. The AUC values were
4.9 ± 1.8 mg·hr/ml for control and 3.7 ± 0.96 mg·hr/ml for ob/
ob mice. This study is the first pharmacokinetic profiling of
rosiglitazone and its metabolites in ob/ob mice as diabetic
animal model.
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Fig. 1 – Plasma concentration–time profiles of rosiglitazone (RSG; A) and its metabolites, N-desmethyl rosiglitazone (N-Dm-
RSG; B) and hydroxy rosiglitazone (OH-RSG; C) after 5 mg/kg dose by intravenous and oral administration in C57/B6 and in
ob/ob mice.
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